{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:20:46Z","timestamp":1781112046964,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00943-2","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:01:41Z","timestamp":1699603301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Michael","family":"Ozga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Huric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94.","journal-title":"Blood Cancer J"},{"key":"943_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116:e56\u201365.","journal-title":"Blood."},{"key":"943_CR3","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","volume":"21","author":"G An","year":"2015","unstructured":"An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21:2148\u201356.","journal-title":"Clin Cancer Res"},{"key":"943_CR4","doi-asserted-by":"publisher","first-page":"34276","DOI":"10.18632\/oncotarget.5371","volume":"6","author":"M Zang","year":"2015","unstructured":"Zang M, Zou D, Yu Z, Li F, Yi S, Ai X, et al. Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH. Oncotarget. 2015;6:34276\u201387.","journal-title":"Oncotarget."},{"key":"943_CR5","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","volume":"29","author":"EM Boyle","year":"2023","unstructured":"Boyle EM, Blaney P, Stoeckle JH, Wang Y, Ghamlouch H, Gagler D, et al. Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma. Clin Cancer Res. 2023;29:3901\u201313.","journal-title":"Clin Cancer Res"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood."},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","volume":"2","author":"M Merz","year":"2018","unstructured":"Merz M, Jauch A, Hielscher T, Bochtler T, Schonland SO, Seckinger A, et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2018;2:1\u20139.","journal-title":"Blood Adv"},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica."},{"key":"943_CR9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","volume":"20","author":"F Cottini","year":"2022","unstructured":"Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. Mol Cancer Res. 2022;20:1083\u201395.","journal-title":"Mol Cancer Res"},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood-2022-168685","volume":"140","author":"S Steiger","year":"2022","unstructured":"Steiger S, Lutz R, Prokoph N, Palit S, Tirier SM, Reichert P, et al. Bone marrow immune signatures in multiple myeloma are linked to tumor heterogeneity and treatment outcome. Blood. 2022;140:2083\u20135.","journal-title":"Blood."},{"key":"943_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u201325.e6.","journal-title":"Cancer Cell"},{"key":"943_CR14","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","volume":"107","author":"T Martin","year":"2022","unstructured":"Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, et al. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022;107:2485\u201391.","journal-title":"Haematologica."},{"key":"943_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93835-z","volume":"11","author":"E Kriegova","year":"2021","unstructured":"Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11:14671.","journal-title":"Sci Rep"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00943-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:04:37Z","timestamp":1699603477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00943-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00943-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}